Recombinant human platelet-activating factor acetylhydrolase for treatment of severe sepsis: Results of a phase III, multicenter, randomized, double-blind, placebo-controlled, clinical trial*
Steven M. Opal(Brown University), John P. Pribble(Apple (Israel)), Luis Jáuregui(Memorial Hospital of Rhode Island), Thierry Dugernier(Clinique Saint Pierre), S. C. Lowry(University of Kent), William T. McGee(Stellenbosch University), Pierre‐François Laterre(Cliniques Universitaires Saint-Luc), Ignace Demeyer(Onze Lieve Vrouwziekenhuis Hospital), Xavier Wittebole(Cliniques Universitaires Saint-Luc), Konrad Reinhart(Charité - Universitätsmedizin Berlin), José A. Lorente(Hospital Universitario de Getafe), Bruno François(Inserm), Edward Abraham(New York Medical College), Ángel Crespo López(Hospital Universitario Infanta Cristina), Miguel Sánchez(Stellenbosch University), Jean-François Dhainaut(Université Paris Cité), S. Kljucar(Stellenbosch University), Brian Warren(Stellenbosch University), Sonia Souza(Stellenbosch University)
Cited by 145
Related Papers
The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)
|JAMA|2016|28.1k
Surviving Sepsis Campaign
|Critical Care Medicine|2013|9.7k
Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock, 2012
|Intensive Care Medicine|2013|7.3k
Efficacy and Safety of Recombinant Human Activated Protein C for Severe Sepsis
|New England Journal of Medicine|2001|6.1k
2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference
|Critical Care Medicine|2003|6k